Skip to content Skip to footer
Close
What is Severe OSA

What Is Severe OSA?

BlogJune 6, 2024863Views0Likes0Comments
Severe Obstructive Sleep Apnea (OSA) is a serious condition that affects many people's sleep and overall health. Many people wonder, what is severe OSA? Severe OSA is a serious sleep disorder where breathing repeatedly stops and starts during sleep due to blocked airways. It leads to significant oxygen drops, frequent awakenings, loud snoring, and extreme daytime…

Read More

What is Moderate OSA

What Is Moderate OSA?

BlogJune 4, 2024933Views0Likes0Comments
Moderate Obstructive Sleep Apnea (OSA) is a common sleep disorder that affects many people. But the question is what is moderate OSA? Moderate OSA occurs when frequent breathing pauses during sleep lead to significant disruptions. Symptoms include loud snoring, daytime fatigue, and mood swings. This level of OSA is serious and can increase the risk of…

Read More

Vivos Q1 Earnings 2024

Vivos Reports First Quarter 2024 Financial Results & Provides Operational Update

Blog, NewsMay 14, 20241KViews0Likes0Comments
May 14, 2024 16:05 ET | Source: Vivos Therapeutics, Inc Vivos Expanding its Revenue Generating Initiatives As Operating Expenses Decrease 22%, Representing Seven Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the…

Read More

Quarter Financial Results

Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call

Blog, NewsMay 14, 20241KViews0Likes0Comments
Call Scheduled for Today, Tuesday, May 14, 2024 at 5:00 pm ET LITTLETON, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of…

Read More

Vivos mmRNA appliance

Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

Blog, NewsApril 8, 20241KViews0Likes0Comments
First Medicare-Accepted Oral Appliance Treatment for All Severities of Obstructive Sleep Apnea in Adults   LITTLETON, Colo., April 9, 2024 -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities…

Read More

Vivos Releases 2023 4th Quarter Financial Results

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

Blog, NewsMarch 28, 20241KViews0Likes0Comments
March 28, 2024 16:05 ET | Source: Vivos Therapeutics, Inc Positive Business Momentum and Sales Pipeline Growth Following FDA 510(k) Clearance of Vivos’ Proprietary Oral Medical Devices to Treat Severe Obstructive Sleep Apnea Annual Operating Expenses Declined 27% Due to Success of Cost Cutting Initiatives Management to Host Conference Call Today at 5:00 pm ET LITTLETON,…

Read More

new technologies to treat Sleep Apnea

New Technologies To Treat Sleep Apnea

BlogMarch 28, 20242KViews1Like0Comments
Sleep apnea is a widespread sleep disorder marked by pauses in breathing or shallow breaths during sleep, that affects countless individuals. These interruptions, which happen multiple times per hour, lead to fragmented sleep and decreased oxygen levels in the blood. Remarkably, in late 2023, Vivos Therapeutics received the first ever FDA 510(k) clearance for an…

Read More